chapter 1 Overview of Hemostasis and Fibrinolysis -- chapter 2 A Survey of Animal Models to Develop Novel Antithrombotic Agents -- chapter 3 Design Issues in Clinical Trials of Thrombolytic and Antithrombotic Agents -- chapter 4 Overview of New Anticoagulant Drugs -- chapter 5 Low-Molecular-Weight Heparins in Acute Coronary Syndromes -- chapter 6 Low-Molecular-Weight Heparin Use in Pregnancy -- chapter 7 Antithrombotic Therapy and Cancer -- chapter 8 Thrombosis Prophylaxis with Low-Molecular-Weight Heparin in Medical Patients -- chapter 9 Low-Molecular-Weight Heparins in Prevention and Treatment of Venous Thromboembolism -- chapter 10 Low-Molecular-Weight Heparin in the Pediatric Population -- chapter 11 New Indications for Low-Molecular-Weight Heparins -- chapter 12 Clinical Use of Argatroban -- chapter 13 Hirudin for Acute Coronary Syndromes -- chapter 14 Clinical Development of Bivalirudin -- chapter 15 Development of a Synthetic Heparin Pentasaccharide as an Antithrombotic Agent -- chapter 16 Oral-Direct Thrombin Inhibitors -- chapter 17 Orally Active Heparin -- chapter 18 Tissue Factor Pathway Inhibitor: Potential Implications in the Treatment of Cardiovascular Disorders -- chapter 19 Modulation of the Protein C Pathway as a Therapy for Thrombosis -- chapter 20 Soluble Thrombomodulin -- chapter 21 Overview: Antiplatelet Therapy -- chapter 22 Abciximab -- chapter 23 Eptifibatide: A Potent Inhibitor of the Platelet Receptor Integrin, Glycoprotein IIb=IIIa / chapter 24 Tirofiban: A Paradigm for ‘‘Small-Molecule’’ Glycoprotein IIb=IIIa Receptor Antagonists? -- chapter 25 Procoagulant Activities of Glycoprotein IIb=IIIa Receptor Blockers / chapter 26 Inhibitors of von Willebrand Factor Binding to Platelet Glycoprotein Ib -- chapter 27 Thienopyridines: Ticlopidine and Clopidogrel -- chapter 28 Oral Antiplatelet Therapies Beyond Aspirin and Thienopyridines -- chapter 29 Overview of New Therapeutic Agents -- chapter 30 Clinical and Preclinical Profile of the Novel Recombinant Plasminogen Activator Reteplase -- chapter 31 Tenectaplase: Biochemistry, Pharmacology, and Clinical Experience -- chapter 32 Lanoteplase -- chapter 33 Monteplase: Pharmacological and Clinical Experience -- chapter 34 Pharmacological Action of and Clinical Experience with Pamiteplase, a Novel, Modified, Tissue-Type Plasminogen Activator -- chapter 35 Recombinant, Glycosylated Prourokinase: Preclinical and Clinical Studies -- chapter 36 A Mutant Form of Prourokinase That Spares Hemostatic Fibrin -- chapter 37 Recombinant Staphylokinase for Thrombolytic Therapy -- chapter 38 Desmodus rotundus (Vampire Bat) Plasminogen Activator DSPAa1: A Superior Thrombolytic Created by Evolution -- chapter 39 Alfimeprase -- chapter 40 In Vitro and In Vivo Models to Investigate Clot Lysis and Thrombolysis -- chapter 41 Thrombolysis and Ultrasound.